Severe pulmonary hypertension associated with the acute motor sensory axonal neuropathy subtype of Guillain-Barré syndrome Kris A. Rooney, MD; Neal J. Thomas, MD, MSc G uillain-Barré syndrome (GBS) consists of a group of autoimmune disorders that generally manifest as symmetric, progressive, ascending paralysis. There are five subtypes of GBS, with acute inflammatory demyelinating polyradiculoneuropathy (AIDP) being the most common ( Table 1) . The annual frequency of GBS is between 1 and 3 per 100,000 population and increases with advancing age. Roughly 30% of patients with GBS require mechanical ventilation during the course of their illness (1) . The axonal forms of GBS tend to be more clinically severe than AIDP, with frequent respiratory involvement, ventilator dependence, prolonged hospitalization, and longterm neurologic deficits (2) .
Autonomic involvement has been described in all subtypes including cardiovascular, vasomotor, or pseudomotor dysfunction of both the sympathetic and parasympathetic systems. Some patients manifest hyperactivity of the sympathetic system whereas others show autonomic hypofunction (3) . Specific autonomic symptoms include arrhythmias, hypertension, postural hypotension, labile blood pressure, hypersalivation, disordered sweating, gastrointestinal dysmotility, pupillary abnormalities, urinary sphincter disturbances, and abnormal vasomotor tone causing flushing and venous pooling (4) .
Despite evidence of vasomotor dysfunction in GBS, the association between the development of this autoimmune disease and pulmonary hypertension has not previously been reported. Pulmonary hypertension is defined as a mean pulmonary artery pressure Ն25 mm Hg at rest or Ն30 mm Hg during exercise with normal pulmonary artery occlusion pressure and an increased pulmonary vascular resistance. The pathogenesis of pulmonary hypertension is complex and likely multifactorial. Endothelial dysfunction, abnormal vascular responses, platelet dysfunction, and genetic predisposition all seem to play a role in the disease state (5).
We report a case of a young child with a severe form of acute motor sensory axonal neuropathy (AMSAN) subtype of GBS and significant pulmonary hypertension. As it is impossible to demonstrate cause and effect from the data available in this retrospective report, it is clear that the diagnosis and aggressive treatment of this potentially fatal syndrome likely contributed to an excellent outcome.
CASE PRESENTATION
The requirement for Institutional Review Board approval was waived for this case report.
A 3-yr-old girl presented to a tertiary care pediatric intensive care unit from a local emergency department with cardiovascular collapse secondary to respiratory failure requiring intubation. She was in her usual state of health until approximately 6 wks before hospital admission, when she suffered a diarrheal illness with some vomiting. Shortly after this illness, she began complaining of pain and weakness in her legs. She was evaluated by her family physician and underwent a basic rheumatologic work-up, which was undiagnostic. The pain and weakness in her lower extremities worsened, and after several weeks, she was unable to walk. Her family also noted that her eyelids seemed to be drooping for several days before hospital admission. On the day of admission, she had shallow breathing and was therefore taken to the emergency department, where she was found to be in respiratory failure with reported values of PCO 2 , 87 torr (11.6 kPa) and SaO 2 ϭ 84%. She was intubated and initiated on mechanical ventilation before transfer to our unit.
On arrival to the pediatric intensive care unit, the patient was in fulminant cardiovascular collapse with a blood pressure of 59/20 mm Hg. She was mottled and cool with significantly prolonged capillary refill, thready pulses, and no urine output. Lungs were clear to auscultation bilaterally. Cardiac examination revealed tachycardia, with a 2/6 systolic ejection murmur heard loudest along the left sternal border. A soft liver edge was palpable 2 cm below the costal margin. An arterial blood gas measurement revealed a severe metabolic acidosis, with a calculated base deficit of 18 mL/kg. Oxygenation was maintained with an FIO 2 ranging from 70% to 100%.
After 60 mL/kg of fluid resuscitation, bicarbonate administration, and the addition and escalation of vasopressor support (including dobutamine, vasopressin, and epinephrine infusions), her blood pressure and perfusion improved slightly. Chest radiograph revealed cardiomegaly without evidence of an acute lung process. An echocardiogram performed once the patient was stabilized revealed right ventricular enlargement with septal bowing, trace regurgitation of the tricuspid valve (the jet seemed to be an incomplete envelope, and therefore right ventricular pressures could not be estimated), and an estimate of severely elevated pulmonary artery pressures. The patient was started on inhaled nitric oxide to manage her pulmonary hypertension, and a repeat echocardiogram performed on 40 parts per million was unable to estimate right ventricular pressures but revealed subjectively that the "ventricular septal profile is remarkably improved and less flattened compared to the study prenitric oxide." Furthermore, the patient's oxygenation index improved by Ͼ40% with the addition of nitric oxide in the absence of any other ventilatory changes, from 17.4 prenitric oxide to 12.1 after the addition of this pulmonary vasodilator. Shortly afterward, a pulmonary artery catheter was inserted to monitor her pulmonary artery pressures and cardiac indices. She improved significantly on the nitric oxide, classifying her as a responder to acute vasodilator testing ( Table 2) .
The differential diagnosis for this disease process was extensive, including numerous neurologic, infectious, rheumatalogic, hematologic, metabolic, and toxic etiologies for her symptoms. She underwent a thorough workup once her condition stabilized. Cerebrospinal fluid studies done on hospital day 4 yielded the equivocal result of high-normal protein concentration (0.5 g/dL) without pleocytosis. Ultimately, on hospital day 8, electromyography and muscle/nerve biopsy established her diagnosis. The biopsy revealed active degeneration of motor and sensory nerve axons with secondary atrophic muscle changes. There was no evidence of demyelination or inflammatory response. Multiple and special stains revealed no evidence of a metabolic disorder. These findings are consistent with AMSAN (Fig. 1) . Electromyographic findings were also consistent with AMSAN. The patient was treated with two cycles of intravenous immunoglobulin (IVIG) and gradually her symptoms improved. She was weaned off nitric oxide on day 6, but her pulmonary hypertension recurred requiring nifedipine and subsequent transition to once-daily amlodipine. She was extubated successfully after 13 days of mechanical ventilation and was able to move all four extremities, albeit weakly.
Ultimately, the patient required 23 total days of intensive care. She was discharged to inpatient rehabilitation, where she spent 10 days, during which time her lower extremity strength gradually improved. On admission to the rehabilitation unit, her leg strength was rated 2 of 5 and her feet were held in plantar flexion. Arm strength was normal. By discharge home, she was walking with a rolling walker and assistance, bearing weight on both feet and initiating steps consistently. She was able to sit without support and progress from sit to stand with minimal assistance.
At her 1-mo follow-up appointments, the patient no longer showed evidence of pulmonary hypertension on echocardiogram and the amlodipine was discontinued. Neurologically, she was able to sit up and stand against a wall and reportedly was making slow progress. After these initial visits, the patient was unfortunately lost to follow-up.
DISCUSSION
Guillain-Barré syndrome consists of autoimmune disorders that generally manifest as symmetric, progressive, ascending paralysis. There are five subtypes of GBS: AIDP, acute motor axonal neuropathy, AMSAN, Miller Fisher syndrome, and acute panautonomic neuropathy, with AIDP being the most common ( Table 2) . A preceding illness can be identified in approximately two-thirds of patients with respiratory infections and gastroenteritis being the most commonly associated diseases (4). Most often, the inciting organism is not identified, but with preceding diarrheal illness, Campylobacter jejuni is commonly isolated (6) . Patients with documented C. jejuni infection have been shown to develop the axonal variants of GBS more commonly than the demyelinating form (4) . The pathogenesis of Campylobacter-associated GBS is described as "molecular mimicry." The infection is thought to elicit an immune response where antibodies formed against the bacteria cross-react with axolemmal antigens, thus damaging the peripheral nerves (6) .
GBS begins with a progressive phase, lasting several days to several weeks. This progressive phase is followed by a plateau phase, usually reached by 4 wks, during which symptoms remain unchanged (1). Recovery time varies greatly. IVIG and plasma exchange are the standard medical treatments for GBS. A large multicenter randomized trial compared the efficacy of plasma exchange with IVIG and combined therapy. IVIG was found to be as effective as plasma exchange and there was no additional benefit to combining therapies (7) . IVIG has accelerated recovery in children with GBS who were unable to walk (8) . Approximately 80% of patients with GBS achieve a full recovery within 12 to 18 mos.
A retrospective study done by Tekgul et al (9) examined features of demyelinating vs. axonal forms of GBS in 23 children. More patients with axonal forms presented with cranial nerve involvement than in the demyelinating group, with severe autonomic disturbance observed in 80% of patients with AMSAN compared with only mild autonomic dysfunction in 20% of patients with AIDP. Respiratory failure was noted in 54% of patients with axonal GBS compared with only 10% with AIDP. Pediatric intensive care unit stay was longest in those children with AMSAN, with overall mean hospital stay being longer in the axonal group than the demyelinating group (9) .
Pulmonary hypertension is a previously unreported complication of GBS. The most common etiologies of pulmo- nary hypertension are secondary to chronic disorders of the respiratory system or congenital heart disease. Other causes include chronic sleep apnea, neuromuscular diseases, interstitial lung disease, autoimmune disorders, and primary pulmonary vascular disease. Primary pulmonary vascular disease includes primary pulmonary hypertension, veno-occlusive diseases, invasive pulmonary hemangiomatosis, and pulmonary embolic diseases (10) . The diagnosis of pulmonary hypertension requires an elevated mean pulmonary artery pressure with normal pulmonary artery occlusion pressure (Ͻ15 mm Hg) and an increased pulmonary vascular resistance index Ն3 Wood units per m 3 (11) . Treatment of pulmonary hypertension generally involves first determining if the elevation in pulmonary vascular resistance is fixed or variable by performing an acute reversibility study with a short-acting vasodilator. Suitable agents include inhaled nitric oxide, intravenous epoprostenol, inhaled iloprost, or intravenous adenosine. A response is defined as a decrease in mean pulmonary artery pressure of Ͼ20% without a decrease in cardiac output. Responders can often be managed chronically with calcium-channel blockers. Other agents used to treat pulmonary hypertension include endothelin receptor antagonists, prostacyclin and prostacyclin analogs, anticoagulants, phosphodiesterase inhibitors, elastase inhibitors, and oxygen (11) .
We present the case of a young girl with a severe form of acute sensory motor axonal neuropathy and pulmonary hypertension. There are likely multiple factors that contributed to the development of pulmonary hypertension in this patient. First, the autonomic dysfunction that is commonly seen in GBS could have contributed to not only the systemic blood pressure lability seen in our patient but also to the development of pulmonary vasoconstriction and thus pulmonary hypertension. This theory is plausible based on Downing and Lee's work on the role of the autonomic nervous system in pulmonary circulation (12) . Both sympathetic and parasympathetic fibers are found in close association with the pulmonary vasculature, with distribution being most intense in the larger elastic vessels. Studies done with canines demonstrated that stimulation of the sympathetic chain consistently elicits an increase in pulmonary artery pressure, averaging 10% to 15% of resting pressure. Likewise, injection of norepinephrine causes an increase in calculated pulmonary resistance as well as reduced compliance (12) . The dysautonomia associated with AMSAN may have triggered similar responses in the patient's pulmonary vascular bed.
Another important factor in the development of pulmonary hypertension was the progressive decline in the patient's respiratory status. It is plausible that she had been hypoventilating for several days to weeks before presentation due to weakening respiratory musculature. It is known that children have a greater vasoreactive response to hypoventilation than adults. Children with symptoms of exertional or nocturnal syncope have been found to have a high-normal resting pulmonary artery pressure that increases markedly with acute periods of exercise as well as with modest systemic arterial oxygen desaturation during sleep (11) . Therefore, even a modest decrease in systemic arterial oxygen saturation could have predisposed our patient to the development of pulmonary hypertension once her respiratory status declined further.
Embolic disease is another potential cause of pulmonary hypertension. Although a definitive diagnostic study for pulmonary emboli was not performed in this case, it is possible that the patient had some thrombus formation secondary to her immobility. It had been over 1 month that the patient was unable to ambulate, secondary to leg pain and weakness before presentation. This immobility could have placed her at risk for deep vein thrombosis with resultant pulmonary embolic events.
Based on this patient, it seems as if pulmonary hypertension can be associated with GBS complicated by hypoventilation and hypoxemia. Although we cannot offer definitive proof that the pulmonary hypertension occurred as a direct result of GBS, it is plausible based on the pathophysiologic changes that occur with GBS. Pulmonary venous thrombosis cannot be ruled out in this at-risk patient and may have contributed to her clinical presentation. Autonomic dysfunction secondary to GBS may have also contributed to the severity of her pulmonary hypertension. It is possible that other individuals suffering from severe forms of GBS, especially those with significant autonomic dysfunction, may actually have undiagnosed pulmonary hypertension that requires therapy. Therefore, it is recommended that clinicians caring for critically ill children with GBS have a high index of suspicion for pulmonary hypertension, and consider echocardiogram and possibly placement of a pulmonary artery catheter to guide therapy if there are clinical signs of this potentially fatal process.
